Background: The aim of our study was to describe a large population with anomalies involving the SHOX region, responsible for idiopathic short stature and Léri-Weill dyschondrosteosis (LWD), and to identify a possible genotype/phenotype correlation. Methods: We performed a retrospective multicenter study on French subjects with a SHOX region anomaly diagnosed by multiplex ligation-dependent probe amplification or Sanger sequencing. Phenotypes were collected in each of the 7 genetic laboratories practicing this technique for SHOX analysis. Results: Among 205 index cases and 100 related cases, 91.3% had LWD. For index cases, median age at evaluation was 11.7 (9.0; 15.9) years and mean height standard deviation score was -2.3 ± 1.1. A deletion of either SHOX or PAR1 or both was found in 74% of patients. Duplications and point mutations/indels affected 8 and 18% of the population, respectively. Genotype-phenotype correlation showed that deletions were more frequently associated with Madelung deformity and mesomelic shortening in girls, as well as with presence of radiologic anomalies, than duplications. Conclusions: Our results highlight genotype-phenotype relationships in the French population with a SHOX defect and provide new information showing that clinical expression is milder in cases of duplication compared to deletions.

van Duyvenvoorde HA, Lui JC, Kant SG, Oostdijk W, Gijsbers ACJ, Hoffer MJV, Karperien M, Walenkamp MJE, Noordam C, Voorhoeve PG, Mericq V, Pereira AM, Claahsen-van de Grinten HL, van Gool SA, Breuning MH, Losekoot M, Baron J, Ruivenkamp CAL, Wit JM: Copy number variants in patients with short stature. Eur J Hum Genet 2014;22:602-609.
Beiser KU, Glaser A, Kleinschmidt K, Scholl I, Röth R, Li L, Gretz N, Mechtersheimer G, Karperien M, Marchini A, Richter W, Rappold GA: Identification of novel SHOX target genes in the developing limb using a transgenic mouse model. PLoS One 2014;9:e98543.
Marchini A, Marttila T, Winter A, Caldeira S, Malanchi I, Blaschke RJ, Häcker B, Rao E, Karperien M, Wit JM, Richter W, Tommasino M, Rappold GA: The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes. J Biol Chem 2004;279:37103-37114.
Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54-63.
Benito-Sanz S, Thomas NS, Huber C, del Blanco DG, Aza-Carmona M, Crolla JA, Maloney V, Argente J, Campos-Barros Á, Cormier-Daire V, Heath KE: A novel class of pseudoautosomal region 1 deletions downstream of SHOX is associated with Léri-Weill dyschondrosteosis. Am J Hum Genet 2005;77:533-544.
Chen J, Wildhardt G, Zhong Z, Roth R, Weiss B, Steinberger D, Decker J, Blum WF, Rappold G: Enhancer deletions of the SHOX gene as a frequent cause of short stature: the essential role of a 250 kb downstream regulatory domain. J Med Genet 2009;46:834-839.
Sabherwal N, Bangs F, Röth R, Weiss B, Jantz K, Tiecke E, Hinkel GK, Spaich C, Hauffa BP, van der Kamp H, Kapeller J, Tickle C, Rappold G: Long-range conserved non-coding SHOX sequences regulate expression in developing chicken limb and are associated with short stature phenotypes in human patients. Hum Mol Genet 2007;16:210-222.
De Sanctis V, Tosetto I, Iughetti L, Antoniazzi F, Clementi M, Toffolutti T, Facchin P, Monti E, Pisanello L, Tonini G, Greggio NA: The SHOX gene and the short stature. Roundtable on diagnosis and treatment of short stature due to SHOX haploinsufficiency: how genetics, radiology and anthropometry can help the pediatrician in the diagnostic process, Padova (April 20th, 2011). Pediatr Endocrinol Rev 2012;9:727-733.
Ogata T: SHOX haploinsufficiency and overdosage: impact of gonadal function status. J Med Genet 2001;38:1-6.
Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, Ross JL, Niesler B: Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet 2007;44:306-313.
Seki A, Jinno T, Suzuki E, Takayama S, Ogata T, Fukami M: Skeletal deformity associated with SHOX deficiency. Clin Pediatr Endocrinol 2014;23:65-72.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM; 2007 ISS Consensus Workshop participants: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210-4217.
Rappold GA: Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab 2002;87:1402-1406.
Binder G: Short stature due to SHOX deficiency: genotype, phenotype, and therapy. Horm Res Paediatr 2011;75:81-89.
Belin V, Cusin V, Viot G, Girlich D, Toutain A, Moncla A, Vekemans M, Merrer ML, Munnich A, Cormier-Daire V: SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nat Genet 1998;19:67-69.
Huber C, Cusin V, Le Merrer M, Mathieu M, Sulmont V, Dagoneau N, Munnich A, Cormier-Daire V: SHOX point mutations in dyschondrosteosis. J Med Genet 2001;38:323.
Benito-Sanz S, Barroso E, Heine-Suñer D, Hisado-Oliva A, Romanelli V, Rosell J, Aragones A, Caimari M, Argente J, Ross JL, Zinn AR, Gracia R, Lapunzina P, Campos-Barros A, Heath KE: Clinical and molecular evaluation of SHOX/PAR1 duplications in Léri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS). J Clin Endocrinol Metab 2011;96:E404-E412.
Thomas NS, Harvey JF, Bunyan DJ, Rankin J, Grigelioniene G, Bruno DL, Tan TY, Tomkins S, Hastings R: Clinical and molecular characterization of duplications encompassing the human SHOX gene reveal a variable effect on stature. Am J Med Genet A 2009;149A:1407-1414.
Ross JL, Scott C Jr, Marttila P, Kowal K, Nass A, Papenhausen P, Abboudi J, Osterman L, Kushner H, Carter P, Ezaki M, Elder F, Wei F, Chen H, Zinn AR: Phenotypes associated with SHOX deficiency. J Clin Endocrinol Metab 2001;86:5674-5680.
Rosilio M, Huber-Lequesne C, Sapin H, Carel J-C, Blum WF, Cormier-Daire V: Genotypes and phenotypes of children with SHOX deficiency in France. J Clin Endocrinol Metab 2012;97:E1257-E1265.
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
Benito-Sanz S, Gorbenko Del Blanco D, Aza-Carmona M, Magano LF, Lapunzina P, Argente J, Campos-Barros Á, Heath KE: PAR1 deletions downstream ofSHOX are the most frequent defect in a Spanish cohort of Léri-Weill dyschondrosteosis (LWD) probands. Hum Mutat 2006;27:1062.
Gatta V, Antonucci I, Morizio E, Palka C, Fischetto R, Mokini V, Tumini S, Calabrese G, Stuppia L: Identification and characterization of different SHOX gene deletions in patients with Leri-Weill dyschondrosteosys by MLPA assay. J Hum Genet 2006;52:21-27.
Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. 1977. Biotechnol Read Mass 1992;24:104-108.
Sempé M, Hansson Bondallaz C, Limoni C: Growth curves in untreated Ullrich-Turner syndrome: French reference standards 1-22 years. Eur J Pediatr 1996;155:862-869.
Wolters B, Lass N, Wunsch R, Böckmann B, Austrup F, Reinehr T: Short stature before puberty: which children should be screened for SHOX deficiency? Horm Res Paediatr 2013;80:273-280.
Huber C: High incidence of SHOX anomalies in individuals with short stature. J Med Genet 2006;43:735-739.
Mazzanti L, Matteucci C, Scarano E, Tamburrino F, Ragni MC, Cicognani A: Auxological and anthropometric evaluation in skeletal dysplasias. J Endocrinol Invest 2010;33(suppl 6):19-25.
Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, Kalifa G, Deal C, Drop SLS, Rappold G, Cutler GB: GH Treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial. J Clin Endocrinol Metab 2013;98:E1383-E1392.
Funari MFA, Jorge AAL, Souza SCAL, Billerbeck AEC, Arnhold IJP, Mendonca BB, Nishi MY: Usefulness of MLPA in the detection of SHOX deletions. Eur J Med Genet 2010;53:234-238.
Bunyan DJ, Baffico M, Capone L, Vannelli S, Iughetti L, Schmitt S, Taylor E-J, Herridge AA, Shears D, Forabosco A, Coviello DA: Duplications upstream and downstream of SHOX identified as novel causes of Leri- Weill dyschondrosteosis or idiopathic short stature. Am J Med Genet A 2016;170A:949-957.
Tropeano M, Howley D, Gazzellone MJ, Wilson CE, Ahn JW, Stavropoulos DJ, Murphy CM, Eis PS, Hatchwell E, Dobson RJB, Robertson D, Holder M, Irving M, Josifova D, Nehammer A, Ryten M, Spain D, Pitts M, Bramham J, Asherson P, Curran S, Vassos E, Breen G, Flinter F, Ogilvie CM, Collier DA, Scherer SW, McAlonan GM, Murphy DG: Microduplications at the pseudoautosomal SHOX locus in autism spectrum disorders and related neurodevelopmental conditions. J Med Genet 2016;53:536-547.
Benito-Sanz S, Aza-Carmona M, Rodriguez-Estevez A, Rica-Etxebarria I, Gracia R, Campos-Barros A, Heath KE: Identification of the first PAR1 deletion encompassing upstream SHOX enhancers in a family with idiopathic short stature. Eur J Hum Genet 2012;20:125-127.
Benito-Sanz S, Royo JL, Barroso E, Paumard-Hernández B, Barreda-Bonis AC, Liu P, Gracía R, Lupski JR, Campos-Barros Á, Gómez-Skarmeta JL, Heath KE: Identification of the first recurrent PAR1 deletion in Léri-Weill dyschondrosteosis and idiopathic short stature reveals the presence of a novel SHOX enhancer. J Med Genet 2012;49:442-450.
Leka SK, Kitsiou-Tzeli S, Kalpini-Mavrou A, Kanavakis E: Short stature and dysmorphology associated with defects in the SHOX gene. Hormones (Athens) 2006;5:107-118.
Albuisson J, Schmitt S, Baron S, Bezieau S, Benito-Sanz S, Heath KE: Clinical utility gene card for: Leri-Weill dyschondrosteosis (LWD) and Langer mesomelic dysplasia (LMD). Eur J Hum Genet 2012, DOI: 10.1038/ejhg.2012.64.
Niesler B, Röth R, Wilke S, Fujimura F, Fischer C, Rappold G: The novel human SHOX allelic variant database. Hum Mutat 2007;28:933-938.
Gatta V, Palka C, Chiavaroli V, Franchi S, Cannataro G, Savastano M, Cotroneo A, Chiarelli F, Mohn A, Stuppia L: Spectrum of phenotypic anomalies in four families with deletion of the SHOX enhancer region. BMC Med Genet 2014;15:87.
Bunyan DJ, Taylor E-J, Maloney VK, Blyth M: Homozygosity for a novel deletion downstream of the SHOX gene provides evidence for an additional long range regulatory region with a mild phenotypic effect. Am J Med Genet A 2014;164A:2764-2768.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.